Bioretec Ltd's financials for Jan-Dec 2025: Net sales EUR 3,522k (-22.5% vs 2024), EBITDA EUR -8,476k. Strategy update for 2026–2028.

Bioretec Ltd posted its financial statements for January to December 2025, revealing a decrease in net sales to EUR 3,522 thousand compared to the previous year's EUR 4,544 thousand. Sales margin also decreased to EUR 2,314 thousand, and EBITDA was EUR -8,476 thousand. The company's result for the period amounted to EUR -9,483 thousand. The Board of Directors proposed no dividend be distributed for the financial period. Despite an increase in R&D expenditure, the equity ratio stood above 84%. Cash and cash equivalents dropped to EUR 4,126 thousand, and earnings per share were negative. The number of undiluted shares increased to 30,788,092. Further details are available at the company's website.